Literature DB >> 28476205

Therapeutic efficacy of human umbilical cord mesenchymal stem cells transplantation against renal ischemia/reperfusion injury in rats.

Sohair R Fahmy1, Amel M Soliman1, Mervat El Ansary2, Samah Abd Elhamid3, Heba Mohsen1.   

Abstract

BACKGROUND: Acute kidney injury (AKI) is a common clinical problem raising the urgent needs to develop new strategies for treatment. The present study investigated the therapeutic potential of human umbilical cord - mesenchymal stem cells (HUC-MSCs) transplantation against renal ischemia/reperfusion injury (IRI) in rats.
METHODS: Twenty four male Wistar rats were assigned into two main groups, sham group (control group) and I/R group. I/R group was injected in the tail vein with either phosphate buffer saline (PBS) or HUC-MSCs.
RESULTS: The HUC-MSCs improved kidney injury induced by I/R as demonstrated by enhancement of the kidney function via decreasing serum levels of creatinine, urea and uric acid. The therapeutic efficacy of HUC-MSCs were found to be mediated through anti-oxidant activity as indicated by significant reduction in total malondialdehyde (MDA) and significant increment in the levels of reduced glutathione (GSH), catalase (CAT) and glutathione-S-transferase (GST).
CONCLUSION: The present work suggests that HUC-MSCs may be an effective therapeutic agent against renal IRI. The recorded data showed improvement of renal functions and urine albumin in HUC-MSCs than IRI group with positive antioxidant efficacy of HUC-MSCs through scavenging free radicals and supporting the antioxidant enzymes.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antioxidant enzymes; Control group (sham group); Human umbilical cord- mesenchymal stem cells (HUC-MSCs); Oxidative stress; Renal ischemia/reperfusion injury

Mesh:

Year:  2017        PMID: 28476205     DOI: 10.1016/j.tice.2017.04.006

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  6 in total

1.  Hypoxic Preconditioning Enhances the Efficacy of Mesenchymal Stem Cells-Derived Conditioned Medium in Switching Microglia toward Anti-inflammatory Polarization in Ischemia/Reperfusion.

Authors:  Han Yu; Zhihong Xu; Gaojing Qu; Huimin Wang; Lulu Lin; Xianyu Li; Xiaolin Xie; Yifeng Lei; Xiaohua He; Yun Chen; Yinping Li
Journal:  Cell Mol Neurobiol       Date:  2020-05-18       Impact factor: 5.046

2.  Extracellular vesicles from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect against renal ischemia/reperfusion injury via delivering specificity protein (SP1) and transcriptional activating of sphingosine kinase 1 and inhibiting necroptosis.

Authors:  Xiaodong Yuan; Dawei Li; Xiaosong Chen; Conghui Han; Longmei Xu; Tao Huang; Zhen Dong; Ming Zhang
Journal:  Cell Death Dis       Date:  2017-12-11       Impact factor: 8.469

3.  Efficacy Evaluation and Tracking of Bone Marrow Stromal Stem Cells in a Rat Model of Renal Ischemia-Reperfusion Injury.

Authors:  Ling-Jie Wang; Chang-Ping Yan; Dan Chen; Ting Xu; Sheng He; Hua Zhang; Cheng Xu; Ying Qiao; Zeng-Yu Jiang; Rui-Ping Zhang; Jian-Ding Li
Journal:  Biomed Res Int       Date:  2019-03-20       Impact factor: 3.411

4.  Transplantation of chicken egg white extract-induced rabbit PBMCs as a treatment for renal ischemia-reperfusion injury in rabbits.

Authors:  Guang-Ping Ruan; Xiang Yao; Qing-Keng Lin; Zi-An Li; Xue-Min Cai; Rong-Qing Pang; Xing-Hua Pan
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

Review 5.  Mesenchymal stromal cells: what have we learned so far about their therapeutic potential and mechanisms of action?

Authors:  Francesco Amadeo; Katherine Trivino Cepeda; James Littlewood; Bettina Wilm; Arthur Taylor; Patricia Murray
Journal:  Emerg Top Life Sci       Date:  2021-10-29

Review 6.  Stem/Stromal Cells for Treatment of Kidney Injuries With Focus on Preclinical Models.

Authors:  Adriana Torres Crigna; Cristina Daniele; Carolina Gamez; Sara Medina Balbuena; Diego O Pastene; Daniela Nardozi; Cinzia Brenna; Benito Yard; Norbert Gretz; Karen Bieback
Journal:  Front Med (Lausanne)       Date:  2018-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.